Cryolife, Inc (Cryolife), is engaged in preserving and distributing human tissues for cardiac and vascular transplant applications and develops and commercializes medical devices. The human tissue distributed by the Company includes the CryoValve SG pulmonary human heart valve (CryoValve SG), processed using CryoLife’s SynerGraft technology. The Company’s medical devices include BioGlue Surgical Adhesive (BioGlue) and Hemostase, which the Company distributes for Medafor, Inc. (Medafor), as well as other medical devices. CryoLife distributes preserved human cardiac and vascular tissue to implanting institutions throughout the United States, Canada and Europe. CryoLife distributes BioGlue throughout the United States and in more than 70 other countries for designated applications. The Company operates in two segments: Preservation Services and Medical Devices.